Trial Profile
A Pilot Study to Determine if Downstream Markers of EGFR Linked Signaling Pathways Predict Response to OSI-774 (Erlotinib) in the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 08 Aug 2007 Status change from recruiting to in progress.
- 10 Jul 2007 Status changed from in progress to recruiting.
- 08 Feb 2007 Status changed from recruiting to in progress